Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Changes in HPV prevalence in Danish women with vulvar cancer during 28 years - A nationwide study of >1300 cancer cases

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Preoperative predictors of inguinal lymph node metastases in vulvar cancer - A nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prognostic value of the 2018 FIGO staging system for cervical cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Vaginal melanoma in Denmark from 1980 to 2018: A population-based study based on genetic profile and survival

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effects of risk factors for ovarian cancer in women with and without endometriosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A nationwide longitudinal study on risk factors for progression of anal intraepithelial neoplasia grade 3 to anal cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Human Papillomavirus Infection Among Pregnant Women Living With HIV: A Systematic Review and Meta-Analysis

    Research output: Contribution to journalReviewResearchpeer-review

  4. Risk of colorectal cancer after use of fertility drugs-results from a large Danish population-based cohort of women with infertility

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Objective: A substantial proportion of vulvar cancers are caused by high-risk human papillomavirus (hrHPV), but hrHPV prevalence in vulvar cancer has mainly been investigated in smaller studies which did not evaluate time trends. Our aim was to assess hrHPV prevalence in >1300 Danish vulvar cancers diagnosed during 1990–2017, including changes in hrHPV prevalence over time. Methods: In a nationwide pathology register, we identified women diagnosed with vulvar cancer at thirteen hospitals from all Danish regions. Archival tumor tissue was collected from local repositories and, upon pathology review, sent to a central laboratory for HPV testing using INNO-LiPA. We calculated hrHPV prevalence according to time, age and histology, and evaluated the overall and age-specific estimated annual percentage change (EAPC). Results: We included 1308 vulvar cancer cases, with a median age of 72 years at diagnosis. The overall hrHPV prevalence was 52.0% (95% CI: 49.3–54.7). HPV types 16/18 were found in 39.6% of cases, whereas nine-valent HPV (9vHPV) vaccine types 16, 18, 31, 33, 45, 52, and 58 were found in 50.8%. The hrHPV prevalence showed an increasing trend over time, with an EAPC of 0.35% (95% CI: 0.00–0.71). The hrHPV prevalence was higher in younger women throughout the study period, and increasing trends over time were seen in both older (age ≥ 60) and younger (age < 60) women. The hrHPV prevalence was higher in non-keratinizing (71.0%) and warty/basaloid (78.0%) carcinomas than in keratinizing (39.4%) and verrucous (36.4%) carcinomas. Conclusions: Our results indicate that the 9vHPV vaccine could potentially prevent a substantial proportion of vulvar cancers in Denmark.

Original languageEnglish
JournalGynecologic Oncology
Volume166
Issue number3
Pages (from-to)589-595
Number of pages7
ISSN0090-8258
DOIs
Publication statusPublished - Sep 2022

Bibliographical note

Copyright © 2022. Published by Elsevier Inc.

    Research areas

  • Aged, Carcinoma, DNA, Viral, Denmark/epidemiology, Female, Humans, Papillomaviridae/genetics, Papillomavirus Infections, Prevalence, Uterine Cervical Neoplasms, Vulvar Neoplasms/pathology

ID: 79051005